Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma

Prior treatment

• Patients with prior systemic anticancer therapy for unresectable or metastatic melanoma;
• Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of treatment;
• Participation in any interventional drug or medical device study within 30 days prior to treatment start;

Other illness

• Patients with previous malignancies unless a complete remission was achieved at least 2 years prior to study entry;
• Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the patient to receive protocol therapy;
• Presence of active, known, or suspected autoimmune disease;
• Patients with active hepatitis B (defined as having a positive hepatitis B surface antigen \[HBsAg\] test at screening) or active C hepatitis or active HIV;
• History of severe hypersensitivity reactions to other monoclonal antibodies;

Other

• Active brain metastases;
• Pregnant and breast-feeding women;
• Patients of reproductive who refuse to use effective methods of contraception.

• Age ≥ 18 years;
• Histologically confirmed stage III (unresectable) or stage IV Cutaneous Melanoma;
• PD-L1 evaluation and as per standard clinical practice, patients with PD-L1 \< 1% will be treated with anti PD1 based regimen and patients with PD-L1\>1% will be treated with anti-PD1 in monotherapy;
• Anti-PD1 (Nivolumab) or anti PD1 based regimen (Nivolumab plus Ipilimumab or Nivolumab plus Relatlimab) planned as per standard clinical practice and decision by the treating oncologist; ;
• Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria;
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1;
• Screening laboratory values must meet the following criteria before starting the treatment:
  • WBCs ≥2000/μL
  • Neutrophils ≥1500/μL
  • Platelets ≥100 x 10³/μL
  • Hemoglobin ≥9.0 g/dL
  • Serum creatinine of ≤1.5 times the upper normal limits or creatinine clearance \>40 mL/minute
  • AST ≤ 3 times the upper normal limits
  • ALT ≤ 3 times the upper normal limits
  • Total bilirubin ≤1.5 times the upper normal limits (except patients with Gilbert Syndrome who must have total bilirubin \<3.0 mg/dL)
• Prior palliative radiotherapy must have been completed at least 2 weeks prior to study drug administration;
• Patients of reproductive potential, must use adequate contraception methods;
• Signed written consent form;